FOLH1 and posterior cortical atrophy: In contrast to PSMA-targeting radioactive agents, which destroy PCa cells anywhere in the body, radium-223 dichloride (Xofigo®, Bayer, Whippany, NJ, USA), an injectable radionuclide, is approved for targeting bone metastasis of ADT-resistant PCa [37].